Table 4.
Expression of interferons and interferon-stimulated genes according to airway obstruction in healthy subjects and COPD patients
| Genes | Healthy subjects (n=35) | Mild to moderate COPD (n=36) | Severe COPD (n=15) | P-value |
|---|---|---|---|---|
| IL-29 | 0 (0–256) | 0 (0–391) | 0 (0–435) | 0.651 |
| IFN-β | 0 (0–56) | 0 (0–263) | 0 (0–557) | 0.330 |
| MxA | 9,979 (1,572–27,126) | 10,401 (1,171–68,816) | 6,742 (0–26,672) | 0.061 |
| OAS | 960 (0–2,393) | 646 (0–3,072) | 459** (0–777) | 0.004 |
| Viperin | 444 (0–2,163) | 926** (0–68,346) | 598 (0–19,218) | 0.006 |
Notes: Data are presented as median (range) copy number per µL of cDNA for each gene of interest. Mild to moderate COPD: post-bronchodilation FEV1 ≥50% predicted. Severe COPD: post-bronchodilation FEV1 <50% predicted. P-values indicate Kruskall–Wallis test;
**
P<0.01 vs healthy subjects.
Abbreviations: FEV1, forced expiratory volume in 1 second; IL-29, interferon lambda1; IFN-β, interferon beta.